AbbVie
Early Avycaz Therapy Increases Success Rates for MDR P. aeruginosa Pneumonia
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa is a prevalent and ...
AUGUST 28, 2023
Right Drug for the HABP and VABP Patient
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are among the most common and ...
AUGUST 23, 2023
FDA Grants Pediatric Indication for Mavyret for HCV
An estimated 23,000 to 46,000 children have HCV infection in the United States.
MAY 1, 2019
FDA Approves Mavyret for HCV Genotypes 1-6
Knowing which of the six distinct HCV genotypes there are can help inform treatment. Approximately 75% of Americans ...
AUGUST 7, 2017
FDA Approves Imbruvica to Treat Adults With Chronic GVHD
Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...
AUGUST 7, 2017
FDA Grants Breakthrough Therapy Designation for AbbVie's Investigational HCV Regimen
Currently in Phase III clinical trials, glecaprevir/pibrentasvir is an investigational, pan-genotypic regimen being ...
SEPTEMBER 30, 2016
